Program
xaluritamig
Also written as “Xaluritamig” and “AMG 509”.
Its studies are mostly in Prostatic Neoplasms · Sarcoma, Ewing, led by Amgen.
Furthest: phase 3, since Nov 14, 20247 company-led studies, 7 open or runningNext primary completion: Feb 17, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 77 open or running | phase 3since Nov 14, 2024 | Dec 16, 2019 | Feb 17, 2027phase 1 · NCT06613100 |
Also a collaborator on its studies: BeOne Medicines.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2019First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04221542 · 505 planned · United States, Australia, China and more
- Aug 13, 2024Phase 1 study in Prostatic NeoplasmsNCT06555796 · 50 enrolled · United States, Australia
- Sep 23, 2024Phase 1 study in Prostatic NeoplasmsNCT06613100 · 40 planned · United States, Germany
- Nov 14, 2024Phase 3 study in NeoplasmsNCT06691984 · 707 enrolled · United States, Australia, Austria and more
- Sep 18, 2025Phase 3 study in Prostatic NeoplasmsNCT07213674 · 750 planned · United States, Australia, Austria and more
- Dec 9, 2025Phase 1 study in Sarcoma, EwingNCT07297979 · 50 planned · United States, Australia
- Mar 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07493512 · 40 planned · United States, Australia
- Nov 12, 2026Primary completion moved from 2030-03-22 to 2030-07-28Date moved laterphase 1 · +4 months · NCT04221542
Ahead
- Feb 17, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06613100
- Mar 13, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06555796
- Jan 2, 2029Primary completion: phase 3 study in NeoplasmsNCT06691984
- Jan 7, 2030Primary completion: phase 3 study in Prostatic NeoplasmsNCT07213674
TargetBeta
“A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against both the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HLX3902 | Fosun Pharma | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07493512Prostatic Neoplasms · United States, Australia | 1 | Recruiting | Jul 30, 2030 | 40 |
| NCT07297979Sarcoma, Ewing · United States, Australia | 1 | Recruiting | May 26, 2030 | 50 |
| NCT07213674Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jan 7, 2030 | 750 |
| NCT06691984Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 2, 2029 | 707 |
| NCT06613100Prostatic Neoplasms · United States, Germany | 1 | Recruiting | Feb 17, 2027 | 40 |
| NCT06555796Prostatic Neoplasms · United States, Australia | 1 | Active, not recruiting | Mar 13, 2027 | 50 |
| NCT04221542Prostatic Neoplasms · United States, Australia, China and more | 1 | Recruiting | Jul 28, 2030 | 505 |
How it is read
Names in the registry
- “Xaluritamig”, 6 entries
- “AMG 509”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 6 studies
- Sarcoma, Ewing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.